Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | ELOVL1 | Q9BW60 | 3/20 | 0.43 |
| ▸ | GCK | P35557 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16703929 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4EALDH1A1LMNAHTT | |
| SCHEMBL16698703 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2KDM4EALDH1A1LMNAHTT | |
| SCHEMBL16703930 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2KDM4EALDH1A1LMNAHTT | |
| SCHEMBL9233569 | 0.79 | CTSK (0.51) | SMN1; SMN2KDM4EALDH1A1LMNAHTT | |
| SCHEMBL18421576 | 0.76 | NPC1 (0.65) | SMN1; SMN2KDM4EALDH1A1LMNAHTT | |
| SCHEMBL12649503 | 0.74 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4EALDH1A1LMNAHTT | |
| SCHEMBL11565633 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2KDM4EALDH1A1LMNAHTT | |
| SCHEMBL2629347 | 0.72 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM4EALDH1A1LMNAHTT | |
| SCHEMBL2625578 | 0.72 | NPC1 (0.57) | SMN1; SMN2KDM4EALDH1A1LMNAHTT | |
| SCHEMBL12444121 | 0.71 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066094-B1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-08 | — | — | EP | disclosed |
| US-9890145-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-3066094-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-9321757-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-26 | — | — | US | disclosed |
| WO-2015068856-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133451-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | SMN1; SMN2 1888/4885KDM4E 125/4885ALDH1A1 782/4885 |
| US-20150133451-A1 | HETEROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | SMN1; SMN2 1888/4885KDM4E 125/4885ALDH1A1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.